Saturday, July 11, 2026

Drug profile · INN

prolia

prolia is a tumor necrosis factor ligand superfamily member 11 inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — prolia
Class
Route
Patents
0
Programs
1
Data quality
0.70

Quick answer

prolia is a tumor necrosis factor ligand superfamily member 11 inhibitor.

Key facts

INN prolia
Mechanism Tumor necrosis factor ligand superfamily member 11 inhibitor
Target Tumor necrosis factor ligand superfamily member 11

Mechanism of action

Tumor necrosis factor ligand superfamily member 11 inhibitor

Primary target: Tumor necrosis factor ligand superfamily member 11

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. LY06006/MRCT-301 Phase 3 · Createrna Science and · Postmenopausal osteoporosis

Related & competitor drugs

  1. denosumab Musculo-skeletal system (M05)
  2. denosumab-bbdz Tumor necrosis factor ligand superfamily member 11 inhibitor

Frequently asked questions

What is prolia?

prolia is a tumor necrosis factor ligand superfamily member 11 inhibitor.